Welcome to the e-CCO Library!

P669: Effect of vedolizumab therapy on whole blood transcriptional profiles in patients with Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Haglund, S.(1,2,3);Söderman, J.(1,3);Almer, S.(2,4);
Created: Wednesday, 2 June 2021, 4:12 PM
P669: Human β-defensin 2 suppresses TNF-α secretion in human and mouse dendritic cells mediated by chemokine receptor-2
Year: 2018
Source: ECCO '18 Vienna
Authors:

N.S. Armbruster1, K. Sidelmann Brinch2, B. Andersen2, E.F. Stange1, N. Malek1, P. Nordkild3, J. Wehkamp1*

Created: Thursday, 21 February 2019, 9:14 AM
P669: Improving Crohn's disease stricture dilation outcome: Effect of repeated dilation, needle knife stricturotomy, and ongoing active inflammation
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Schulberg, J.D.(1,2)*;Hamilton, A.L.(1,2);Wright, E.K.(1,2);Holt, B.(1,2);Sutherland, T.(2,3);Ross, A.L.(1);Vogrin, S.(2);Kamm, M.A.(1,2);
Created: Friday, 14 July 2023, 11:12 AM
P669: Transmural healing is associated with higher infliximab trough levels in Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Albshesh1, B. Unger1,2, S. Ben Horin2, R. Eliakim2, U. Kopylov2, D. Carter*2

Created: Friday, 22 February 2019, 9:41 AM
P669: Validation of prior infliximab exposure and total colectomy outcome in patients with ulcerative colitis in Sweden
Year: 2022
Source: ECCO'22
Authors: Huang, Z.(1);Hill, D.(1);Bengtsson, C.(2);Wang, M.(2);Hakkarainen, K.M.(3);Hellström, P.M.(4);
Created: Friday, 11 February 2022, 3:56 PM
P670 Usefulness of monitoring the concentration of azathioprine metabolites in the children with inflammatory bowel disease and autoimmune hepatitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

K. Bąk-Drabik1, J. Duda-Wrońska2, D. Dąbrowska-Piechota2, P. Adamczyk3

Created: Thursday, 30 January 2020, 10:12 AM
P670: Comparative efficacy on steroid-free remission of pharmacological therapies for moderate-to-severe ulcerative colitis: A systematic review and network meta-analysis
Year: 2018
Source: ECCO '18 Vienna
Authors:

P. Paschos1,2, A. Katsoula3, O. Giouleme3*, A. Tsapas1,4

Created: Thursday, 21 February 2019, 9:14 AM
P670: Evaluating the management of Vitamin D in Crohn's disease patients in a secondary care population
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ahmed R., O'Connell G., Love M., Davis J., Cooney R., Pathmakanthan S., Iqbal T., Bhala N.

Created: Wednesday, 20 February 2019, 10:36 AM
P670: Familial Inflammatory Bowel Disease is associated with a more adverse disease compared to sporadic cases
Year: 2022
Source: ECCO'22
Authors: Boaz, E.(1);Ariella, B.G.S.(2);Menachem, S.(2);Eran, G.(2);Petachia, R.(1);Shlomo, Y.(1);Koslowsky, B.(2);
Created: Friday, 11 February 2022, 3:56 PM
P670: Identification of two additional susceptibility loci for Crohn's disease in Koreans
Year: 2021
Source: ECCO'21 Virtual
Authors: Lee, H.S.(1);Jung, S.(1);Ye, B.D.(2);Baek, J.(1);Park, D.(1);Park, S.H.(2);Yang, S.K.(2);Song, K.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P670: Therapeutic efficacy and economic impact of half sulfasalazine therapy for refractory ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Kunisaki*1, M. Tatsuno1, J. Kouyama1, C. Kawamoto1, H. Nishioka1, A. Mizoguchi1, Y. Nakamori1, T. Mitsui1, K. Chida1, Y. Hashimoto1, Y. Tamura1, A. Ikeda1, T. Ogashiwa1, R. Suzuki2, S. Maeda3, H. Kimura1

Created: Friday, 22 February 2019, 9:41 AM
P670: “What Matters To You?” – How do patient views compare with a patient experience framework and UK national standards of care?
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Sheldon, E.(1)*;Roman, S.(2);Randall, K.(2);Rachel, H.(3);Winsor, G.(4);Wakeman, R.(5);Lobo, A.(2);
Created: Friday, 14 July 2023, 11:12 AM
P671 Natural history and clinical outcomes of patients with ulcerative colitis who are intolerant to 5-aminosalicylic acid agents: A multi-centre cohort study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Madarame1, H. Kinoshita1, T. Yamaguchi1, Y. Izumi1, Y. Nishikawa1, S. Shonai1, M. Tatsuno1, Y. Ishii1, K. Yaguchi1, Y. Nakamori1, A. Ikeda1, K. Araki1, A. Hirayama1, T. Ogashiwa1, A. Fuji1, R. Suzuki2, H. Kimura1, R. Kunisaki1

Created: Thursday, 30 January 2020, 10:12 AM
P671: Calprotectin does not add accuracy to PRO2 for prediction of continuous clinical response in moderate-to-severe ulcerative colitis patients treated with golimumab
Year: 2018
Source: ECCO '18 Vienna
Authors:

F. Cornillie1*, L. Peyrin-Biroulet2, J. Long3, G. Philip3

Created: Thursday, 21 February 2019, 9:14 AM
P671: Early suppression of the serological macrophage activity biomarker VICM, and not suppression of CRP, predicts the response to infliximab in Crohn's disease patients
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Mortensen J.H.*1, van Haaften W.T.2,3, Olesen M.L.1,4, Karsdal M.1, Olinga P.2, Dijkstra G.3, Bay-Jensen A.-C.1

Created: Wednesday, 20 February 2019, 10:36 AM
P671: Effect of genetic polymorphisms in the folate pathway on the efficacy and safety of methotrexate in Crohn’s disease.
Year: 2021
Source: ECCO'21 Virtual
Authors: Salazar, J.(1);Gordillo Abalos, J.(2);Fernández, A.(3);Esteve, M.(4);Pérez Gisbert, J.(5);Busquets, D.(6);Lucendo, A.(7);Márquez, L.(8);Guardiola, J.(9);Martin, M.D.(10);Iglesias, E.(11);Monfort, D.(12);Villoria, A.(13);Cañete, F.(14);Bell, O.(1);Ricart, E.(3);Zabana, Y.(4);Domènech, E.(14);Garcia-Planella, E.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P671: Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands: a retrospective observational study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. R. White1,2,3, S. Din3, R. Ingram4, S. Foley4, M. A. Alam5, R. Robinson5, R. Francis2, E. Tucker2, M. Jalal6, D. Elphick6, E. Atallah1,7, A. Norman7, M. Amin8, A. Sajjad8, N. Heggs9, S. Meadowcroft9, G. Moran*1,2

Created: Friday, 22 February 2019, 9:41 AM
P671: Occurrence and clinical impact of eosinophilic esophagitis in a large cohort of children with Inflammatory Bowel Disease.
Year: 2022
Source: ECCO'22
Authors: Aloi, M.(1);Rossetti, D.(1);Bucherini, S.(1);Felici, E.(2);Romano, C.(3);Martinelli, M.(4);Di Pasquale, V.(5);Lionetti, P.(6);Oliva, S.(7);
Created: Friday, 11 February 2022, 3:56 PM
P671: Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: Results from the UniStar study long-term extension
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Turner, D.(1)*;Rosh, J.R.(2);Cohen, S.A.(3);Griffiths, A.(4);Hyams, J.S.(5);Kierkuś, J.(6);Adedokun, O.J.(7);Strauss, R.(8);Kim, L.(9); Volger, S.(10);
Created: Friday, 14 July 2023, 11:12 AM
P672 The escalation of therapy or intervention (ETI) calculator for ulcerative colitis: does it have the potential to help outpatient capacity meet demand?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A.J. Walsh, L. Matini, R. Kantschuster, M. Lepetyukh, D. Simadibrata, G. Collins, J. Wilson, M. Hussain, A. Tarafdar, O. Brain, R. Palmer, T. Ambrose, J. Satsangi, S.P.L. Travis

Created: Thursday, 30 January 2020, 10:12 AM